Last reviewed · How we verify
Molecular detection of antibiotic resistance
Molecular detection of antibiotic resistance is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development. Also known as: Helicobacter Molecular detection of resistance to clarithromycin and quinolones, Use of triple therapy base on antibiotics resistances (PPI,amoxicillin,clarithromycin, metronidazole).
At a glance
| Generic name | Molecular detection of antibiotic resistance |
|---|---|
| Also known as | Helicobacter Molecular detection of resistance to clarithromycin and quinolones, Use of triple therapy base on antibiotics resistances (PPI,amoxicillin,clarithromycin, metronidazole) |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections
- Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary Hospital (NA)
- Molecular Characterization of Carbapenemase-Producing Enterobacterales (NA)
- Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
- Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt
- Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP (NA)
- Phenotypic and Genotypic Variations of Enterococcus Spp
- Type VI Secretion System in Klebsiella Pneumoniae
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Molecular detection of antibiotic resistance CI brief — competitive landscape report
- Molecular detection of antibiotic resistance updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Molecular detection of antibiotic resistance
What is Molecular detection of antibiotic resistance?
Molecular detection of antibiotic resistance is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris.
Who makes Molecular detection of antibiotic resistance?
Molecular detection of antibiotic resistance is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).
Is Molecular detection of antibiotic resistance also known as anything else?
Molecular detection of antibiotic resistance is also known as Helicobacter Molecular detection of resistance to clarithromycin and quinolones, Use of triple therapy base on antibiotics resistances (PPI,amoxicillin,clarithromycin, metronidazole).
What development phase is Molecular detection of antibiotic resistance in?
Molecular detection of antibiotic resistance is in Phase 1.
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Also known as: Helicobacter Molecular detection of resistance to clarithromycin and quinolones, Use of triple therapy base on antibiotics resistances (PPI,amoxicillin,clarithromycin, metronidazole)
- Compare: Molecular detection of antibiotic resistance vs similar drugs
- Pricing: Molecular detection of antibiotic resistance cost, discount & access